{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Continuous Ropivacaine Infusion for Post-Mastectomy Analgesia"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomized, triple-masked, placebo-controlled trial, 60 subjects undergoing unilateral or bilateral mastectomy were enrolled."
      },
      "Participants": {
        "score": 2,
        "evidence": "The study was conducted at a single hospital, with eligibility criteria including adult patients undergoing mastectomy."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomized to receive either perineural ropivacaine 0.4% or normal saline via portable infusion pumps (5 mL/h basal; 300 mL reservoir)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine the benefits of adding a multiple-day, ambulatory, continuous ropivacaine paravertebral nerve block to a single-injection ropivacaine block following mastectomy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was average pain on postoperative day (POD) 1, measured on a 0\u201310 scale."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Participants, clinicians, and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "60 subjects undergoing unilateral or bilateral mastectomy were enrolled."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "the median pain score for the ropivacaine group (n=30) was 2 (interquartile range 0\u20133), compared to 4 (1\u20135) for the saline group (n=30; 95% CI difference in medians, \u22124.0 to \u22120.3; P = 0.021)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "the median pain score for the ropivacaine group (n=30) was 2 (interquartile range 0\u20133), compared to 4 (1\u20135) for the saline group (n=30; 95% CI difference in medians, \u22124.0 to \u22120.3; P = 0.021)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}